NGS Sample Preparation Market

Updated on : March 06, 2023

The global NGS sample preparation market in terms of revenue was estimated to be worth $1.9 billion in 2022 and is poised to reach $4.0 billion by 2028, growing at a CAGR of 13.4% from 2022 to 2028. The key factors driving the growth of the market are use of NGS as substitute for PCR, and greater efficiency of genotyping and preparation protocols. However, ethical and privacy issues in health data are expected to restrain market growth to a certain extent.

Attractive Opportunities in the NGS Sample Preparation Market

To know about the assumptions considered for the study, Request for Free Sample Report

NGS Sample Preparation Market Dynamics

DRIVERS: Greater efficiency of genotyping and preparation protocols

Human whole genome sequencing has been growing exponentially in recent years and has created a new benchmark for itself in the bacterial infection outbreak owing to its high resolution available for genotyping. NGS sample preparation has  turned out to be the biggest technology  for bacterial outbreak investigation owing to its application in genotyping. Illumina devices are used on the highest scale in the process of NGS sample preparation, but protocols from other key players like ThermoFisher and PerkinElmer can also be performed. Enzymatic fragmentation library preparation have an upper hand over the other protocols, owing to its properties of minimal hands-on time, and the ability to work with small quantities of DNA.

RESTRAINTS: Presence of alternative technologies

Presence of other techniques such as Sanger, antigen tests, polymerase chain reaction (PCR), and serological tests are used for the diagnosis of various diseases. For the past two decades, Sanger sequencing has dominated genomic research and achieved a number of significant accomplishments in the field of genomics. Serological tests are used for the determination of viruses in the body by screening antibodies in the blood. Serological tests are also used for the detection of a number of antibodies that are produced by the immune system.

OPPORTUNITES: Increasing collaborations and partnerships among key playerS

Many key players, such as Illumina, Thermo Fisher Scientific, and PerkinElmer, are collaborating with other research laboratories, academic institutes, hospitals, clinics, and other pharmaceutical & biotechnology companies. Owing to these strategies, the market is experiencing an introduction of new technologies, products, and research projects. These projects are expected to provide lucrative growth opportunities for market players owing to the rising adoption of NGS sample preparation.

CHALLENGES: Ethical and privacy issues in health data

The rise in population-based sequencing has resulted in several concerns related to the privacy of health data generated. For instance, there are concerns over the possibility of giant software companies engaged in NGS data management selling genomic data.

Non-invasive prenatal testing (NIPT) detects and analyzes fetal DNA in maternal blood to identify genetic and chromosomal conditions in the first trimester of pregnancy. It helps identify pregnant women at an increased risk of having a child with an abnormality. However, this testing procedure currently faces significant ethical issues and policy challenges. The ethical issues include the consequences of informed decision-making, such as enabling women to prepare for a child with a condition or trait, rights of people with disabilities, and sex-selective abortions.

The DNA accounted for the largest share of the sample type segment in NGS sample preparation market in 2022.

Based on sample type, the market is categorized into DNA, and RNA. In 2022, the DNA segment accounted for the largest share of the market. Rising number of cancer cases and growing R&D investments for studying DNA samples is expected to drive the growth of the DNA segment during the forecast period.

The workstation/ instruments segment dominated the product & services segment in NGS sample preparation market in 2022.

Based on the product & services, the segment is categorized into workstation/ instruments, reagents & consumables and services. In 2022, the workstation/ instruments segment dominated the product segment with the highest revenue share. Increasing demand for automation of NGS estimated to drive the market growth.

In 2022, the disease diagnostics segment have generated highest revenue in the application segment for NGS sample preparation market.

Based on the application, the Market is segmented into disease diagnostics, drug discovery, agricultural & animal research, and other applications. In 2022, the disease diagnostics segment have generated highest revenue in the application segment. The large share of the disease diagnostics segment can be attributed to the rising cases of cancer all over the globe and early diagnosis of various infectious diseases and monogenetic disorders, as well as in precision medicine.

North America was the largest market for NGS Sample Preparation Market in 2022.

Geographically, the market is segmented into North America, Europe, Asia Pacific, and MEA. The market is dominated by North America in 2022 and this dominance is anticipated to continue throughout the forecast period. The large share of the segment can be attributed to the favorable initiatives by government and private bodies for the adoption of NGS technologies, advancements in NGS sample preparation products, the growing prevalence of target diseases, an increasing number of NGS-based research & clinical applications, growing research on cancer, the rising awareness of NGS services, and the presence of leading NGS service providers, such as Illumina (US), Thermo Fisher Scientific (US), and Agilent Technologies (US), are driving the growth of the NGS market in North America.

To know about the assumptions considered for the study, download the pdf brochure

The prominent players in the NGS sample preparation market are Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), PerkinElmer Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Agilent Technologies, Inc. (US), Danaher (US), Becton, Dickinson and Company (US), Merck KGAA (Germany), QIAGEN (Germany),  Bio-Rad Laboratories, Inc. (US), Promega Corporation (US), Eurofins Scientific (Luxembourg), BGI (China), 10x Genomics (US), Sysmex Corporation (US), Psomagen (US), Zymo Research Corporation (US), Takara Bio Inc. (Japan), Novogene Co., Ltd. (China), New England Biolabs (US), Tecan Trading AG (US), Oxford Nanopore Technologies PLC (UK), PacBio (US), Medgenome (US), and Swift Biosciences Inc. (US).

NGS Sample Preparation Market Report Scope

This report categorizes the NGS sample preparation market into the following segments & sub-segments:

By Products & Services

• Workstations/Instruments
• Reagents & Consumables
• Services

By Workflow

• DNA Fragmentation & Library Preparation
• Target Enrichment
• QC

By Sample Type

• DNA
• RNA

By Method

• Manual Sample Preparation
• Microfluidic Sample Preparation
• Automated Liquid Handling-based Sample Preparation

By Application

• Diagnostics
• Drug Discovery
• Agricultural & Animal Research
• Others

By End User

• Academic Institutes & Research Centers
• Hospitals & Clinics
• Pharma & Biotech Companies
• Other End Users

By Region

• North America
  • US
  • Canada
• Europe
  • Germany
  • France
  • UK
  • Rest of Europe (RoE)
• Asia Pacific (APAC)
  • Japan
  • India
  • China
  • Australia
  • South Korea
  • Rest of Asia Pacific (RoAPAC)
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East and Africa

Recent Developments

• In 2021, Agilent completed the acquisition of Resolution Bioscience, a leader in the development and commercialization of NGS-based precision oncology solutions. Resolution Bioscience complemented and expanded Agilent’s capabilities in NGS-based cancer diagnostics and provided the company with innovative technology to further serve the needs of the fast-growing precision medicine market.
• In 2020, Roche announced that it has entered into a 15-year, non-exclusive partnership with Illumina to broaden the adoption of distributable next-generation sequencing (NGS) based testing in oncology.
• In 2021, Thermo Fisher Scientific announced the acquisition of clinical research services provider PPD.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst